Article

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025

2022-07-10

Abstract excerpt

The Cancer Genome Atlas has clarified that about 50% of high-grade serous ovarian cancer shows homologous recombination deficiency (HRD). However, the frequency of HRD in Japanese patients with ovarian cancer remains unclear. The aim of JGOG3025 study ( NCT03159572 ) is to identify the frequency of HRD in Japanese patients with ovarian cancer. The JGOG3025 study is a multicenter collaborative prospective observati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4e7dd4ac-6b5d-573c-8c59-8a979ea9bb6c
DOI: 10.1101/2022.07.06.22277241

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025DOI 10.1101/2022.07.06.22277241Read

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 StudySemantic proximity Read

Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset.Semantic proximity Read

Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patientsSemantic proximity Read

Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.Semantic proximity Read

The clinical pathological characteristics and prognostic Relevance of Homologous Recombination Repair Gene Mutations in Ovarian Cancer Patients：A Retrospective Cohort StudySemantic proximity Read

Homologous recombination deficiency in ovarian high-grade serous carcinoma by self-reported raceSemantic proximity Read

[Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing].Semantic proximity Read

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read

Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancersSemantic proximity Read

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.Semantic proximity Read